Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information available about these patients' long term survival and quality of life. There is little Canadian data regarding ICU survival and regarding 1-year survival and functional outcomes in this group of patients. Over 500 patients are admitted annually to Canadian ICUs with an underlying hematologic malignancy or stem cell transplant, yet there is a paucity of up to date long-term outcome data. This information will facilitate a better understanding who would best benefit from critical care interventions and the impact of critical illness on their level of function at 1 year as well as survival.
| Facility | City | Region | Status |
|---|---|---|---|
| Foothills Hospital | Calgary | Alberta | |
| University of Alberta | Edmonton | Alberta | |
| Vancouver General Hospital | Vancouver | British Columbia | |
| University of Manitoba | Winnipeg | Manitoba | |
| Queen Elizabeth II Health Sciences Centre | Halifax | Nova Scotia | |
| Juravinski Hospital | Hamilton | Ontario | |
| Kingston General Hospital | Kingston | Ontario | |
| Ottawa Hospital | Ottawa | Ontario | |
| Sunnybrook Health Sciences Centre | Toronto | Ontario | |
| Mount Sinai Hospital | Toronto | Ontario | |
| University Health Network | Toronto | Ontario | |
| Maisonneuve-Rosemont Hospital | Montreal | Quebec | |
| Royal Victoria Hospital | Montreal | Quebec |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03449953 on ClinicalTrials.gov ↗ ← All trials in Canada